In GBM, tumor cells generated fibrinogen-like protein 2 (FGL2), which interfered with GM-CSF signaling, inhibiting the activation of CD103+ cDC1s, decreasing the CD8+ T-cell response, and allowing the tumor to escape immune surveillance [142]. The gene discussed is CD8A; the disease is glioblastoma.